# Formal Conformance Report: Multi-Indication Technical & Scientific Architecture Specification v2.0

**Audited Date:** 2026-09-17T14:43:55.024Z
**Governing Specification:** `public/guides/MAGNIOM-Multi-Indication Technical & Scientific Architecture Specification v2.0.md`
**Scope:** All 107 numbered sections across 15 canonical architectural verification clusters.
**Conformance Status:** ✅ 100% CONFORMANT (15/15 Clusters Passed)

---

## Executive Summary

This report certifies comprehensive technical and scientific compliance with the canonical MAGNIOM v2.0 Architecture charter. The platform enforces strict structural separation between the Indication-Neutral Core and Indication Modules, guarantees fail-closed access controls, prohibits global clinical mode, and validates all 107 sections under IEC 62304 / ISO 14971 standards.

---

## Cluster-by-Cluster Conformance Results

| Cluster | Sections | Architectural Focus | Status | Verification Details |
|---|---|---|---|---|
| **Cluster 1** | §1–§3 | Executive Definition & Governing Principles | ✅ PASS | Governing principle established; 9 discrete IndicationModuleStatus states verified (§1–§3). |
| **Cluster 2** | §4–§11 | Multi-Indication Portfolio & Evidence Readiness | ✅ PASS | All 8 portfolio indications implemented with evidence readiness specifications (§4–§11). |
| **Cluster 3** | §12–§15 | Canonical Objects, Releases & Multi-Condition Cases | ✅ PASS | IndicationModule, IndicationModuleRelease, and multi-condition CaseIndication contracts verified (§12–§15). |
| **Cluster 4** | §16–§19 | Clinical Context, Disease Stages & Lesion-Aware Targeting | ✅ PASS | ClinicalObjective, DiseaseStageContext, LesionContext, and lesion cavity rejection verified (§16–§19). |
| **Cluster 5** | §20–§26 | Target Geometry Taxonomy & Treatment Context | ✅ PASS | All 6 Target Geometries and TreatmentContextRequirement contracts verified (§20–§26). |
| **Cluster 6** | §27–§31 | Multimodal Measurement & Reliability Bundles | ✅ PASS | MeasurementBundle and ReliabilityBundle with provenance manifests verified (§27–§31). |
| **Cluster 7** | §32–§36 | Target Engine v2, Generator Contracts & Indication Context | ✅ PASS | ResolvedTargetEngineContextV2, IndicationTargetingContext, and hermetic isolation verified (§32–§36). |
| **Cluster 8** | §37–§60 | Indication Modules, Target Families & Connectomics | ✅ PASS | All 8 Indication Plugins (Pain, Stroke Motor/Aphasia, OCD, TBI, Tinnitus, PTSD, MDD) active (§37–§60). |
| **Cluster 9** | §61–§67 | Phenotype Extensions, Evidence Graph v2 & Normative Models | ✅ PASS | IndicationPhenotypeExtension, EvidenceKnowledgeGraphV2, and normative integration verified (§61–§67). |
| **Cluster 10** | §68–§69 | Database v2 Architecture & Non-Over-JSON Storage | ✅ PASS | Additive database migrations 043–051 present with relational schemas (no over-JSONing) (§68–§69). |
| **Cluster 11** | §70–§75 | Target Slate v2, Module Comparison & §74 Abstentions | ✅ PASS | All 11 §74 abstention classes and deterministic fallback to evidence prior verified (§70–§75). |
| **Cluster 12** | §76–§80 | Application Shell, Module Navigation & Visual Safety | ✅ PASS | Stable shell architecture, neutral navigation without diagnosis lists, and research visual safety verified (§76–§80). |
| **Cluster 13** | §81–§87 | Policy Governance, Requirements Catalog & Traceability | ✅ PASS | All v2 architecture requirement namespaces (IND, STR, PAI, TBI, TIN) traced against 20 risk controls (§81–§87). |
| **Cluster 14** | §88–§96 | Golden Suites G20–G30, Validation Order & Regression Gate | ✅ PASS | All 11 Golden Cases G20–G30 and all 18 Historical MDD regression cases G01–G18 verified (§88–§96). |
| **Cluster 15** | §97–§107 | Regulatory Integrity, Technology Stack Conservatism & Manifesto | ✅ PASS | §98 Non-Transitive validation, §101 Anti-Global Clinical Mode, §105 Technology Stack Conservatism (SOUP/RLS/Pure Compute/No LLM), and §107 Manifesto verified (§97–§107). |

---

## Key Architectural Invariants Verified

1. **Governing Rule (§2)**: One platform governance architecture, multiple indication models.
2. **Status Distinction (§3)**: Platform support $\ne$ clinical validation. 9 discrete lifecycle states.
3. **Multi-Condition Cases (§14)**: Clinical role differentiation (`primary_targeting_indication`, `secondary_condition`, `contextual_comorbidity`).
4. **Lesion-Aware Safety (§19)**: Automatic rejection of necrotic cavity targets; ipsilesional perimeter targeting.
5. **Geometry Taxonomy (§20–§23)**: Discrimination over 6 canonical target geometries (Point, Somatotopic, Coil-Field, Surface ROI, Volumetric ROI, Network).
6. **Multimodal Ingestion (§27–§31)**: Standardized `MeasurementBundle` and modality-specific `ReliabilityBundle` with SHA-256 provenance.
7. **Hermetic State Isolation (§36)**: Zero cross-module state leakage across indication invocations.
8. **Structured Abstention (§74)**: All 11 discrete abstention classes with deterministic fallback to evidence prior.
9. **Golden Validation Matrix (§88, §96)**: 100% pass rate across G20–G30 v2 Golden Cases and bitwise identical G01–G18 MDD historical regression gate.
10. **Non-Transitive Qualification (§98)**: One indication validation does not confer transitive validity to another.
11. **Anti-Global Mode (§101)**: Clinical authority granted per (Release, Module, Policy) tuple; global `clinical_mode = true` flag strictly prohibited.
12. **Technology Stack Conservatism (§105)**: IEC 62304 §5.3.3 SOUP management, storage-level RLS over client ORMs, containerized neurocompute isolation, and absolute prohibition of probabilistic LLMs in clinical target ranking.

---

## Regulatory Conclusion

The codebase exhibits **100.0% structural, algorithmic, and governance conformance** to `MAGNIOM-Multi-Indication Technical & Scientific Architecture Specification v2.0.md`.